Avelumab

Merck Highlights Commitment to Improving Cancer Outcomes at ASCO 2023

Retrieved on: 
Thursday, May 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Carcinoma, Abstract, Abstract (summary), Maintenance, Health care, FRCP, INSIGHT, Fighter Interception Development Unit RAF, Survival, Cancer, Royal Marsden Hospital, Marriott Marquis, Head, NSCLC, Cisplatin, Lung cancer, Cetuximab, Neck, Doctor of Philosophy, Continental, The Royal Marsden NHS Foundation Trust, ASCO, FRCR, American Society of Clinical Oncology, UC, Patient, RAS, Apoptosis, Annual general meeting, MET, IAP, LA, Institute of Cancer Research, Congress, African Continental Free Trade Area, Phase, RT, Society, Avelumab, Safety, Pharmaceutical industry, Hotel, McCormick Place, SCCHN, Merck

Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US.

Key Points: 
  • Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US.
  • “The research we will present at ASCO 2023 demonstrates that we are not only maximizing the impact of our standard-of-care treatments but also advancing development programs focused on synergistic approaches targeting key cancer pathways and mechanisms,” said Victoria Zazulina, M.D., Head of Development Unit, Oncology, for the Healthcare business of Merck.
  • This study is assessing xevinapant plus RT in patients with resected, high-risk LA SCCHN who are not eligible for cisplatin.
  • Additional presentations for TEPMETKO include analyses from the INSIGHT 2 study in EGFRm METamp NSCLC for patients treated with TEPMETKO plus osimertinib.

EMD Serono Highlights Commitment to Improving Cancer Outcomes at ASCO 2023

Retrieved on: 
Thursday, May 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Carcinoma, Abstract, Abstract (summary), Maintenance, FRCP, INSIGHT, Fighter Interception Development Unit RAF, Health care, Survival, Cancer, Royal Marsden Hospital, Merck Group, Head, NSCLC, Cisplatin, Lung cancer, Neck, Doctor of Philosophy, Continental, The Royal Marsden NHS Foundation Trust, ASCO, FRCR, American Society of Clinical Oncology, UC, Patient, Apoptosis, Annual general meeting, MET, IAP, LA, Merck, Institute of Cancer Research, African Continental Free Trade Area, Merck Serono, Phase, RT, Society, Avelumab, Safety, Pharmaceutical industry

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago.

Key Points: 
  • EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago.
  • This study is assessing xevinapant plus RT in patients with resected, high-risk LA SCCHN who are not eligible for cisplatin.
  • Additional presentations for TEPMETKO include analyses from the INSIGHT 2 study in EGFRm METamp NSCLC for patients treated with TEPMETKO plus osimertinib.
  • In addition to the data being presented at ASCO 2023, EMD Serono will launch a new educational initiative for oncology professionals on the unmet medical need in LA SCCHN, cancer’s resistance to apoptosis, and the role of apoptosis proteins.

Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 15, 2023
PDAC, Neoplasm, Merck Group, Cash, Patient, H. Lee Moffitt Cancer Center & Research Institute, American College, Three Months, Eurosport 1, University, Disease, MRK, Immunity, Research, GPCR, Security (finance), Drug discovery, FDA, Merck Sharp & Dohme Federal Credit Union, B cell, Abstract, G protein-coupled receptor, CCD8, Cancer, Immunotherapy, NDD, SEMA4D, Security, HD, ICIS, SIGNAL, Nature Medicine, Neurodegenerative disease, Nature Communications, Pfizer, Type, ASCO, CO, State Administrative Expenses, Annual general meeting, Tumor microenvironment, Avelumab, Breast cancer, Pharmaceutical industry, Vaccine, Cryptocurrency, Merck

ROCHESTER, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease (NDD) and cancer through the inhibition of SEMA4D today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update on key programs and financing in the first five months of the year.

Key Points: 
  • We expect to meet with our collaborator, Merck, in early June to review the results and consider plans for continued development of this novel immunotherapy combination.
  • Vaccinex plans to complete the interim analysis in May and to publicize results in June, 2023 after meeting with Merck to discuss the next steps.
  • Financial Results for the Three Months Ended March 31, 2023:
    Cash and Cash Equivalents and Marketable Securities.
  • Research and development expenses for the quarter ended March 31, 2023 were $3.8 million as compared to $3.0 million for the comparable period in 2022.

TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor

Retrieved on: 
Monday, May 15, 2023
Heart, TILT, Northwest Biotherapeutics, Pfizer, Docrates Cancer Center, Cancer, SCCHN, Merck Group, Head, Immunotherapy, Neck, Patient, Melanoma, Potyvirus, Cytokine, Avelumab, Pharmaceutical industry

HELSINKI, Finland, May 15, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the first patient has been dosed in a Phase I trial of the company’s oncolytic adenovirus TILT-123.

Key Points: 
  • HELSINKI, Finland, May 15, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the first patient has been dosed in a Phase I trial of the company’s oncolytic adenovirus TILT-123.
  • The study is part of TILT Biotherapeutics’ agreement with Merck KGaA, Darmstadt, Germany and Pfizer, Inc. to evaluate this combination in patients with solid tumors refractory to immune checkpoint inhibitors.
  • It treats cancer by working synergistically with immune checkpoint inhibitors, such as avelumab, in solid tumors.
  • The company is advancing its pipeline of programs including its lead asset TILT-123, in further clinical trials, including in combination with immune checkpoint inhibitors.

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

Retrieved on: 
Monday, May 1, 2023
Carcinoma, MHC, Cancer, Paul Ehrlich Institute, Merck Group, Bladder cancer, ASX, B cell, Cell, Transitional cell carcinoma, IMM, National Cancer Institute, Death, MHC class II, Patient, Autoimmune disease, Research, Vaccine, Eftilagimod alpha, PD-L1, Avelumab, Safety, Transitional epithelium, Pharmaceutical industry, Biomedicine

SYDNEY, AUSTRALIA, May 01, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory approval from the Paul-Ehrlich-Institut (“PEI”), German Federal Institute for Vaccines and Biomedicines, to initiate INSIGHT-005, an investigator-initiated, open-label Phase I trial evaluating the safety and efficacy of eftilagimod alpha (“efti”) in combination with BAVENCIO® (avelumab) in up to 30 patients with metastatic urothelial carcinoma.

Key Points: 
  • Urothelial carcinoma is the most common type of bladder cancer.
  • “We are excited to get this important trial underway.
  • Encouragingly, deep and durable responses were achieved in patients with low or negative PD-L1 expression as well as immuno-oncology insensitive tumours.
  • INSIGHT currently consists of 5 different arms from stratums A to E (INSIGHT-005 is Stratum E).

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

Retrieved on: 
Thursday, March 30, 2023
Beauty micrometer, University, Therapy, ALL, Clinical trial, Doctor of Philosophy, TCR, Science, National Cancer Institute, University of Regensburg, Investigational New Drug, Bone marrow, R, Merck Serono, FDA, IND, Pharmaceutical industry, Vaccine, Blinatumomab, MD, Avelumab

HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company’s Board of Directors, effective immediately.

Key Points: 
  • HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company’s Board of Directors, effective immediately.
  • “We extend our gratitude to Chris for his invaluable contributions to Alaunos during his tenure, and welcome Robert to the Alaunos Board,” said Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos.
  • “Robert brings deep expertise in the discovery and development of engineered T-cell receptor therapies and a background in cellular immunology and translational science.
  • Dr. Hofmeister received his Ph.D. from the University of Regensburg in Germany and completed a postdoctoral fellowship at the National Cancer Institute.

Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)

Retrieved on: 
Monday, March 27, 2023
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Carcinoma, Partnership, Körber Process Solutions, RCC, Health care, Merkel-cell carcinoma, Cancer, Merck Group, UC, Patient, MCC, Renal cell carcinoma, Merck, Merck Serono, Axitinib, PD-L1, Avelumab, Pharmaceutical industry, Angela Merkel, Pfizer

“Our joint efforts have delivered meaningful therapeutic value to patients around the world who are living with cancer.

Key Points: 
  • “Our joint efforts have delivered meaningful therapeutic value to patients around the world who are living with cancer.
  • Merck KGaA, Darmstadt, Germany and Pfizer will continue to operationalize their respective ongoing clinical trials for BAVENCIO, and Merck KGaA, Darmstadt, Germany will control all future research and development activities.
  • As it is currently, product manufacturing and supply chain will remain solely with Merck KGaA, Darmstadt, Germany, ensuring continuous and reliable access to BAVENCIO for patients.
  • The Alliance between Merck KGaA, Darmstadt, Germany and Pfizer was executed in 2014 to co-develop and co-commercialize BAVENCIO with the goal to accelerate development of the human PD-L1 antibody.

Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Carcinoma, Partnership, Speech Processing Solutions, RCC, Health care, Merkel-cell carcinoma, Cancer, Research, UC, Patient, Avelumab, MCC, Renal cell carcinoma, Axitinib, PD-L1, Pharmaceutical industry, Angela Merkel, Merck, Pfizer

Merck today announced it has strengthened its Oncology franchise by regaining exclusive worldwide rights to develop, manufacture, and commercialize anti-programmed death ligand-1 (PD-L1) antibody BAVENCIO® (avelumab) following the termination of their Alliance agreement with Pfizer.

Key Points: 
  • Merck today announced it has strengthened its Oncology franchise by regaining exclusive worldwide rights to develop, manufacture, and commercialize anti-programmed death ligand-1 (PD-L1) antibody BAVENCIO® (avelumab) following the termination of their Alliance agreement with Pfizer.
  • “Our joint efforts have delivered meaningful therapeutic value to patients around the world who are living with cancer.
  • Merck and Pfizer will continue to operationalize their respective ongoing clinical trials for BAVENCIO, and Merck will control all future research and development activities.
  • The Alliance between Merck and Pfizer was executed in 2014 to co-develop and co-commercialize BAVENCIO with the goal to accelerate development of the human anti PD-L1 antibody.

Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Retrieved on: 
Tuesday, March 21, 2023
Survival rate, Neoplasm, Myelocyte, ICIS, SSO, University, PD, ICI, Avelumab, Neurodegenerative disease, Cancer, University of Rochester Medical Center, CD8, International Conference on Population and Development, MD, Patient, TME, PD-1, SEMA4D, Immunosuppression, Tumor microenvironment, B cell, Conference, Safety, Pharmaceutical industry, Vaccine, PDAC

ROCHESTER, N.Y., March 21, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the initiation of a single-arm open label, Phase Ib/2 study to evaluate pepinemab in combination with avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma (PDAC), NCT05102721.

Key Points: 
  • The team received a grant from the Gateway Discovery Award to support the trial concept,” said Maurice Zauderer, CEO of Vaccinex.
  • “Metastatic pancreatic adenocarcinoma is the third leading cause of cancer-related deaths.
  • The profoundly immunosuppressive tumor microenvironment (TME) in PDAC remains a significant barrier to effective cytotoxic and immune based therapies.
  • Tumors that are characterized by a high level of immunosuppressive myeloid cells may be potential candidates for treatment with pepinemab.

New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

Retrieved on: 
Monday, February 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Master of Science, Carcinoma, BSC, Science, Standard of care, OS, ASCO, Immunotherapy, Merck Group, CI, Progress, Carboplatin, Safety, Princess Margaret Cancer Centre, HR, Maintenance, READY, Patient, HIV disease progression rates, RW, Senior, Avelumab, Merck, Survival, Cisplatin, UC, Phase, Tamas, Society, PFS, FRCPC, Doctor of Philosophy, Pharmaceutical industry, Platinum, Jet fuel, Medical imaging, MD

These analyses reinforce the proven survival benefits of BAVENCIO® (avelumab) in the first-line maintenance setting for patients with locally advanced or metastatic urothelial carcinoma (UC).

Key Points: 
  • These analyses reinforce the proven survival benefits of BAVENCIO® (avelumab) in the first-line maintenance setting for patients with locally advanced or metastatic urothelial carcinoma (UC).
  • The findings presented today reinforce that all patients eligible for platinum-based chemotherapy, either cisplatin or carboplatin, can benefit from avelumab maintenance therapy.
  • The analysis also confirmed that the overall survival of BAVENCIO first-line maintenance were similar regardless of whether patients received cisplatin- or carboplatin-based chemotherapy.
  • “BAVENCIO remains the only immunotherapy to show improved overall survival in advanced UC patients in the first-line maintenance setting in a Phase III trial.